Strategies for modifying the chimeric antigen receptor (CAR) to improve safety and reduce toxicity in CAR T cell therapy for cancer

International Immunopharmacology, Journal Year: 2023, Volume and Issue: 125, P. 111093 - 111093

Published: Oct. 26, 2023

Language: Английский

---

Adoptive Transfer of Photosensitizer-Loaded Cytotoxic T Cells for Combinational Photodynamic Therapy and Cancer Immuno-Therapy

Pharmaceutics, Journal Year: 2023, Volume and Issue: 15(4), P. 1295 - 1295

Published: April 20, 2023

Adoptive cell transfer (ACT) has shown remarkable therapeutic efficacy against blood cancers such as leukemia and lymphomas, but its effect is still limited due to the lack of well-defined antigens expressed by aberrant cells within tumors, insufficient trafficking administered T tumor sites, well immunosuppression induced microenvironment (TME). In this study, we propose adoptive photosensitizer (PS)-loaded cytotoxic for a combinational photodynamic cancer immunotherapy. Temoporfin (Foscan®), clinically applicable porphyrin derivative, was loaded into OT-1 (PS-OT-1 cells). The PS-OT-1 efficiently produced large amount reactive oxygen species (ROS) under visible light irradiation in culture; importantly, therapy (PDT) ACT with significant cytotoxicity compared alone unloaded cells. murine lymphoma models, intravenously injected significantly inhibited growth when tissues were locally irradiated light. Collectively, study suggests that PDT mediated provides new approach effective

Language: Английский

---

Challenges in HIV-1 Latent Reservoir and Target Cell Quantification in CAR-T Cell and Other Lentiviral Gene Modifying HIV Cure Strategies

Viruses, Journal Year: 2023, Volume and Issue: 15(5), P. 1126 - 1126

Published: May 9, 2023

Gene-modification therapies are at the forefront of HIV-1 cure strategies. Chimeric antigen receptor (CAR)-T cells pose a potential approach to target infected during antiretroviral therapy or following analytical treatment interruption (ATI). However, there technical challenges in quantification HIV-1-infected and CAR-T setting lentiviral CAR gene delivery also identification expressing antigens. First, is lack validated techniques identify characterize hypervariable HIV gp120 both ART-suppressed viremic individuals. Second, close sequence homology between lentiviral-based modification vectors conserved regions creates vector levels. Consideration needs be taken into standardizing DNA/RNA assays cell other vector-based avoid these confounding interactions. Lastly, with introduction resistance genes cells, need for single-cell resolution determine competence inserts prevent from becoming vivo. As novel continue arise field, resolving CAR-T-cell will crucial.

Language: Английский

---

Update on the current and future use of CAR‐T to treat multiple myeloma

European Journal Of Haematology, Journal Year: 2023, Volume and Issue: 112(4), P. 493 - 503

Published: Dec. 15, 2023

Abstract Chimeric antigen receptor T‐cell (CAR‐T) therapy has become an important intervention in the management of relapsed and relapsed/refractory multiple myeloma (MM). Currently, B‐cell maturation (BCMA) is most targeted surface protein due to its ubiquitous expression on plasma cells, with increasing this essential transmembrane malignant cells as patients develop more advanced disease. This review will explore earliest CAR‐T trials myeloma, discuss issues involved manufacturing processing, well current clinical that led approval two commercially available products, Idecabtagene vicleucel ciltacabtagene autoleucel. The recent data from investigating use earlier line be presented. Finally, problem relapses after presented, including several theories why therapies fail possible caveats. next generation MM‐specific likely include new targets such G‐protein‐coupled class C, Group 5, member D (GPRC5D) signaling lymphocyte activation molecular Family 7 (SLAMF7). role treatment MM undoubtedly increase exponentially decade.

Language: Английский

---

Therapeutic potential of CRISPR/CAS9 genome modification in T cell-based immunotherapy of cancer

Cytotherapy, Journal Year: 2024, Volume and Issue: 26(5), P. 436 - 443

Published: Feb. 23, 2024

Language: Английский

---